TransPerfect enables Karyopharm

to speed up FDA drug approval for myeloma patients

Karyopharm Therapeutics came to TransPerfect with two challenges: ensuring inspection readiness with their trial master file (TMF) and translating more than 60,000 words of crucial documentation for an NDA submission over a weekend.

With TransPerfect's execution of their Trial Interactive technology and TMF and translation services, Karyopharm successfully submitted their drug application in time to meet the FDA deadlines and thereafter received approval of their very first product, XPOVIO.

"I'm writing to express our gratitude for the outstanding work your team at TransPerfect did in support of our NDA filing. We were on a very tight deadline to respond to the FDA, and you completed the work we needed in record time. This is an important moment for Karyopharm, but the people who matter most in this work are myeloma patients and their families. Thank you for everything your team did to support us as we work to bring new options to those suffering from this horrible disease."

—Chief Development Operations Officer
Karyopharm Therapeutics